{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T13:54:01Z","timestamp":1773755641417,"version":"3.50.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.bulcan.2016.10.011","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T04:16:02Z","timestamp":1479442562000},"page":"1035-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lymphomes hodgkiniens et non hodgkiniens des adolescents et des jeunes adultes"],"prefix":"10.1016","volume":"103","author":[{"given":"Sylvain","family":"Garciaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Coso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Brice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9da","family":"Bouabdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bulcan.2016.10.011_bib0410","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/cncr.10403","article-title":"Changing incidence of non-Hodgkin lymphomas in the United States","volume":"94","author":"Clarke","year":"2002","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2016.10.011_bib0415","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1053\/j.seminoncol.2009.07.009","article-title":"Lymphoma in adolescents and young adults","volume":"36","author":"Jaglowski","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2016.10.011_bib0420","series-title":"Cancer epidemiology in older adolescents and young adults 15\u00a0to 29\u00a0years of age, including SEER incidence and survival","author":"Bleyer","year":"1975"},{"issue":"6","key":"10.1016\/j.bulcan.2016.10.011_bib0425","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1634\/theoncologist.11-6-590","article-title":"Cancer in 15- to 29-year-olds by primary site","volume":"11","author":"Bleyer","year":"2006","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bulcan.2016.10.011_bib0430","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2008.07393.x","article-title":"Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science","volume":"144","author":"Hochberg","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.bulcan.2016.10.011_bib0435","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","article-title":"The Soci\u00e9t\u00e9 fran\u00e7aise d\u2019oncologie p\u00e9diatrique LMB89\u00a0protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561\u00a0unselected children with B-cell lymphomas and L3\u00a0leukemia","volume":"97","author":"Patte","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2016.10.011_bib0440","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2005.05735.x","article-title":"The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence","volume":"131","author":"Burkhardt","year":"2005","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.bulcan.2016.10.011_bib0445","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/sj.leu.2401097","article-title":"Epstein-Barr virus and Hodgkin's disease: further evidence for the three-disease hypothesis","volume":"12","author":"Armstrong","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2016.10.011_bib0450","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1038\/ncomms4856","article-title":"A meta-analysis of Hodgkin lymphoma reveals 19p13.3\u00a0TCF3\u00a0as a novel susceptibility locus","volume":"5","author":"Cozen","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2016.10.011_bib0455","series-title":"WHO classification of tumors of the haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"27","key":"10.1016\/j.bulcan.2016.10.011_bib0460","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2016.10.011_bib0465","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.1999.17.12.3736","article-title":"High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90","volume":"17","author":"Schellong","year":"1999","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.bulcan.2016.10.011_bib0470","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002\u00a0study","volume":"28","author":"Mauz-K\u00f6rholz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2016.10.011_bib0475","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/pbc.24279","article-title":"Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group","volume":"59","author":"Tebbi","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2016.10.011_bib0480","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2008-10-184143","article-title":"A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425","volume":"114","author":"Schwartz","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2016.10.011_bib0485","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0950-3536(96)80030-8","article-title":"Treatment of children and adolescents with Hodgkin's disease: the experience of the German-Austrian Paediatric Study Group","volume":"9","author":"Schellong","year":"1996","journal-title":"Bailli\u00e8res Clin Haematol"},{"issue":"18","key":"10.1016\/j.bulcan.2016.10.011_bib0490","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1200\/JCO.2002.12.007","article-title":"Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy","volume":"20","author":"Nachman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2016.10.011_bib0495","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1200\/JCO.2011.41.1819","article-title":"Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma\u00a0\u2013\u00a0a report from the Children's Oncology Group","volume":"30","author":"Wolden","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2016.10.011_bib0500","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-2003-39372","article-title":"Preliminary results of the multicenter trial GPOH-HD 95\u00a0for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook","volume":"215","author":"D\u00f6rffel","year":"2003","journal-title":"Klin P\u00e4diatr"},{"issue":"32","key":"10.1016\/j.bulcan.2016.10.011_bib0505","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.bulcan.2016.10.011_bib0510","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bulcan.2016.10.011_bib0515","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bulcan.2016.10.011_bib0520","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14\u00a0trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2016.10.011_bib0525","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10\u00a0trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bulcan.2016.10.011_bib0530","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2016.10.011_bib0535","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.2012.44.7235","article-title":"Treatment of advanced Hodgkin lymphoma: the more things change, the more they stay the same","volume":"31","author":"Longo","year":"2013","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.bulcan.2016.10.011_bib0540","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10\u00a0years of follow-up of the GHSG HD9\u00a0study","volume":"27","author":"Engert","year":"2009","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.bulcan.2016.10.011_bib0545","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1200\/JCO.2010.33.9549","volume":"29","author":"Borchmann","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9828","key":"10.1016\/j.bulcan.2016.10.011_bib0550","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/S0140-6736(11)61940-5","article-title":"Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15\u00a0trial): a randomised, open-label, phase 3\u00a0non-inferiority trial","volume":"379","author":"Engert","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bulcan.2016.10.011_bib0555","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000\u00a0Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2016.10.011_bib0560","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bulcan.2016.10.011_bib0565","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"15\u00a0Suppl.","key":"10.1016\/j.bulcan.2016.10.011_bib0570","first-page":"8002","article-title":"ABVD (8\u00a0cycles) versus BEACOPP (4\u00a0escalated cycles\u22654\u00a0baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012\u00a0Intergrup randomized phase III clinical trial","volume":"30","author":"Carde","year":"2012","journal-title":"ASCO Meet Abstr"},{"issue":"23","key":"10.1016\/j.bulcan.2016.10.011_bib0575","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood.V126.23.577.577","article-title":"Randomized phase III study comparing an early PET driven treatment de-escalation to a not PET-monitored strategy in patients with advanced stages Hodgkin lymphoma: interim analysis of the AHL2011\u00a0Lysa Study","volume":"126","author":"Casasnovas","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.bulcan.2016.10.011_bib0580","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa022628","article-title":"Involved-field radiotherapy for advanced Hodgkin's lymphoma","volume":"348","author":"Aleman","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2016.10.011_bib0585","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1097\/MPH.0b013e3181f4686e","article-title":"Adolescent hodgkin lymphoma: are treatment results more favorable with pediatric than with adult regimens?","volume":"33","author":"M\u00fcller","year":"2011","journal-title":"J Pediatr Hematol Oncol"},{"issue":"36","key":"10.1016\/j.bulcan.2016.10.011_bib0590","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1200\/JCO.2008.20.2655","article-title":"Hodgkin's lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group","volume":"27","author":"Eichenauer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.bulcan.2016.10.011_bib0595","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2005.04.5823","article-title":"Hodgkin's lymphoma in adolescents","volume":"24","author":"Foltz","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2016.10.011_bib0600","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.bulcan.2016.10.011_bib0605","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1200\/JCO.2003.11.059","article-title":"High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group","volume":"21","author":"Bhatia","year":"2003","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.bulcan.2016.10.011_bib0610","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","article-title":"Breast cancer after chest radiation therapy for childhood cancer","volume":"32","author":"Moskowitz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.bulcan.2016.10.011_bib0615","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.2013.50.6832","article-title":"Stomach cancer risk after treatment for Hodgkin lymphoma","volume":"31","author":"Morton","year":"2013","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.bulcan.2016.10.011_bib0620","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2014.56.7511","article-title":"Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study","volume":"32","author":"Jones","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2016.10.011_bib0625","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S1470-2045(15)70140-3","article-title":"Parenthood in adult female survivors treated for Hodgkin's lymphoma during childhood and adolescence: a prospective, longitudinal study","volume":"16","author":"Br\u00e4mswig","year":"2015","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2016.10.011_bib0630","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2016.10.011_bib0635","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2016.10.011_bib0640","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1\u00a0blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.bulcan.2016.10.011_bib0645","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.2012.43.5800","article-title":"Double-hit diffuse large B-cell lymphoma","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6769","key":"10.1016\/j.bulcan.2016.10.011_bib0650","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.bulcan.2016.10.011_bib0655","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.bulcan.2016.10.011_bib0660","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2005-10-4213","article-title":"Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial","volume":"107","author":"Oschlies","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2016.10.011_bib0665","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bulcan.2016.10.011_bib0670","first-page":"3294","article-title":"Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-M\u00fcnster Group Trial NHL-BFM 90","volume":"94","author":"Reiter","year":"1999","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bulcan.2016.10.011_bib0675","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2016.10.011_bib0680","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB\/LMB 96\u00a0international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.bulcan.2016.10.011_bib0685","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96\u00a0trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2016.10.011_bib0690","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1182\/blood-2006-07-036665","article-title":"Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents","volume":"109","author":"Cairo","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2016.10.011_bib0695","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1054\/bjoc.1999.1083","article-title":"Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002\u00a0protocol","volume":"82","author":"Atra","year":"2000","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2016.10.011_bib0700","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/cncr.20382","article-title":"Long-term results of the first Italian Assciation of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92)","volume":"101","author":"Pillon","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2016.10.011_bib0705","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2016.10.011_bib0710","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2016.10.011_bib0715","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/leu.2010.245","article-title":"Non-Hodgkin's lymphoma in adolescents: experiences in 378\u00a0adolescent NHL patients treated according to pediatric NHL-BFM protocols","volume":"25","author":"Burkhardt","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bulcan.2016.10.011_bib0720","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2012.255","article-title":"Rituximab and FAB\/LMB 96\u00a0chemotherapy in children with Stage III\/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report","volume":"27","author":"Goldman","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bulcan.2016.10.011_bib0725","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.13040","article-title":"Rituximab with chemotherapy in children and adolescents with central nervous system and\/or bone marrow-positive Burkitt lymphoma\/leukaemia: a Children's Oncology Group Report","volume":"167","author":"Goldman","year":"2014","journal-title":"Br J Haematol"},{"issue":"15\u00a0Suppl.","key":"10.1016\/j.bulcan.2016.10.011_bib0730","first-page":"10507","volume":"34","author":"Minard-Colin","year":"2016","journal-title":"ASCO Meet Abstr"},{"issue":"19","key":"10.1016\/j.bulcan.2016.10.011_bib0735","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1200\/JCO.2009.26.6791","article-title":"Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia","volume":"28","author":"Meinhardt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2016.10.011_bib0740","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2016.10.011_bib0745","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jnci\/93.1.22","article-title":"Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study","volume":"93","author":"Kluin-Nelemans","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.bulcan.2016.10.011_bib0750","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2009.12.530","article-title":"Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study","volume":"16","author":"Dilhuydy","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bulcan.2016.10.011_bib0755","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.15_suppl.8503","article-title":"Final results of a randomized phase II GELA\/LYSA study of rituximab plus ACVBP or CHOP, using a PET-driven consolidation strategy, in patients with high-risk diffuse large B-cell lymphoma (DLBCL)","volume":"32","author":"Casasnovas","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bulcan.2016.10.011_bib0760","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1038\/leu.2014.213","article-title":"Excellent outcome of young adults with aggressive non-Hodgkin lymphomas treated with CHOP-like regimens","volume":"28","author":"Hohloch","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bulcan.2016.10.011_bib0765","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.3109\/10428194.2013.858814","article-title":"Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55\u00a0patients","volume":"55","author":"Coso","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.bulcan.2016.10.011_bib0770","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1200\/JCO.2003.08.151","article-title":"Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-M\u00fcnster Group","volume":"21","author":"Seidemann","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2016.10.011_bib0775","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood-2012-04-422709","article-title":"Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB\/LMB96\u00a0mature B-NHL therapy","volume":"121","author":"Gerrard","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bulcan.2016.10.011_bib0780","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/sj.bjc.6601460","article-title":"Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138\u00a0patients treated with CHOP or MACOP-B\/VACOP-B","volume":"90","author":"Todeschini","year":"2004","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2016.10.011_bib0785","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.bmt.1703401","article-title":"Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis","volume":"29","author":"Cairoli","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2016.10.011_bib0790","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/annonc\/mdq418","article-title":"Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study","volume":"22","author":"Rieger","year":"2011","journal-title":"Ann Oncol ESMO"},{"issue":"2","key":"10.1016\/j.bulcan.2016.10.011_bib0795","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1634\/theoncologist.2011-0275","article-title":"Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care","volume":"17","author":"Vassilakopoulos","year":"2012","journal-title":"Oncologist"},{"issue":"17","key":"10.1016\/j.bulcan.2016.10.011_bib0800","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2013.51.7524","article-title":"[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26\u00a0Study","volume":"32","author":"Martelli","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.bulcan.2016.10.011_bib0805","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.bulcan.2016.10.011_bib0405","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1056\/NEJMc1305983","article-title":"Therapy in primary mediastinal B-cell lymphoma","volume":"369","author":"Woessmann","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116302788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455116302788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T10:57:51Z","timestamp":1601204271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455116302788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0007455116302788"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.10.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphomes hodgkiniens et non hodgkiniens des adolescents et des jeunes adultes","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2016.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}